biosyn regulatory documentation

  • biosyn has obtained marketing approval for its lead immunocyanin product IMMUCOTHEL® in the Netherlands, South Korea, Austria and Argentina.
  • IMMUCOTHEL® has been marketed in the Netherlands since 1997, in South Korea and Austria since 2002, in Argentina since 2004/ 2005.
  • biosyn has filed Drug Master Files with the US FDA and Health Canada, for its lead product as well as for VACMUNE® liquid.